Rising Pharmaceuticals launches Edetate calcium disodium injection

Rising Pharmaceuticals, an affiliate of Rising Pharma Holdings, is offering Edetate calcium disodium injection.

This launch will address a critical commercial shortage of this important therapy in the United States, the company noted.

Rising’s Edetate calcium disodium injection is indicated for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults.

[Read more: Challenges continue, but generics companies see a bright future with biosimilars]

“The approval and launch of Rising’s Edetate calcium disodium injection opens access to a critical treatment option for patients exposed to lead poisoning, and further demonstrates Rising’s commitment to addressing product supply shortages for the patients who need them,” said Ira Baeringer, chief operating officer of Rising Pharmaceuticals.

[Read more: Avalere analysis examines Medicare Part D’s plan tier placement of generics]